Typewriter Therapeutics, a portfolio company of AN Venture Partners (ANV), a global bio-venture capital firm and certified VC, is pleased to announce that it has been selected for an award of up to $30 million under the "Strengthening Program for Pharmaceutical Startup Ecosystem" by the Japan Agency for Medical Research and Development (AMED) for the fiscal year 2024.
AMED is an organization dedicated to advancing research and creating supportive environments in the medical field. The "Strengthening Program for Pharmaceutical Startup Ecosystem" is specifically designed to tackle the significant challenge of funding large-scale development projects faced by pharmaceutical start-ups.
By being selected for this prestigious program, Typewriter will be able to expedite the development and commercialization of its gene therapy pipeline for severe genetic disorders using mRNA-based Gene Writing technology, with substantial support from AMED.
Ken Horne, Managing Partner at ANV and CEO of Typewriter Therapeutics commented, “We are delighted that Typewriter Therapeutics has been chosen for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem.’ This new funding will provide Typewriter with the necessary resources to advance our gene therapy development and accelerate our path towards commercialization. ANV, as a certified VC, will continue to support Typewriter in its mission to become a globally recognized bio-venture company.”
About AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem
For more details about the program:
https://www.amed.go.jp/program/list/19/02/005.html
For the results of the recognized VC selection:
https://www.amed.go.jp/koubo/19/02/1902C_00056.html
About Typewriter Therapeutics
Typewriter Therapeutics is a start-up company that focuses on the commercialization of mRNA-based gene therapies using a cutting-edge platform technology that enables the targeted insertion of therapeutic genes. Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. The company aims to provide innovative gene therapies to patients suffering from severe genetic disorders.
About AN Venture Partners
ANV is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.
Media Contacts
Email: info@an.vc